Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05282966

Assessment of QSant™ for Underlying Allograft Rejection

The AQUA registry is a multi-center observational study to assess the clinical management of kidney transplant recipients (KTRs) with use of the QSant test. QSant is a test based on 6 urinary biomarkers including cell-free DNA, that is used for the evaluation and management of acute rejection in renal allograft recipients with clinical suspicion of rejection, as well as subclinical rejection.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The AQUA registry is a multi-center observational study to assess the clinical management of kidney transplant recipients (KTRs) with use of the QSant test. Each participant will be tracked for 24 months. QSant testing will be performed according to the intended use guidelines specified in "LCD - MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38671)", along with all standard of care testing, such as serum creatinine/ estimated glomerular filtration rate (SCr/eGFR) as described in the study schedule. Participants will be compared to a site-specific retrospective cohort of KTRs without QSant testing having received a kidney transplant no more than 5 years prior to study initiation as well as the national cohort derived from UNOS (United Network for Organ Sharing) data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Kidney transplant recipient, ≤ 90 days post kidney transplant of any age, solitary or combined multi-organ solid transplants which includes a kidney transplant.
  • Able to understand risks and requirements of participation and provide informed consent
  • Willing and able to comply with the study requirements

Exclusion criteria

  • Inability to provide a voided urine sample per collection protocol
  • Urological abnormalities such as augmented bladder, ileo-conduits, mitrofanoff, and vesicostomy.

Treatment and study plan

QSant-TM Urine Test

Diagnostic Test

QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.

Other names: QSant(TM), QScore(TM)

Primary outcomes

  1. QScore specificity and sensitivity in relation to kidney biopsy

    Time frame: 6 weeks before each biopsy-proven rejection (BPAR)

    Demonstrate sensitivity and specificity of QSant for detecting biopsy-proven rejection (BPAR), defined as t-score ≥1. For this aim QSant detection will be based on a threshold of >32 within 6 weeks of BPAR (using the most recently collected result)

Study contacts

Contact information is provided by the study sponsor or research team.

Director of Clinical Affairs

CONTACT

[email protected]

650-781-6337

VP of Product Management

CONTACT

[email protected]

833-697-7268

Sponsors and collaborators

Lead sponsor

NephroSant

Industry

Registry information

Official study title

Assessment of QSant™ for Underlying Allograft Rejection (AQUA Registry)

Acronym: AQUA

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Mar 16, 2022
Registry last updated
Sep 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.